{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:47Z","timestamp":1790630387597,"version":"4.1.0"},"reference-count":86,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Non-muscle-invasive bladder cancer (NMIBC) is typically managed with transurethral resection and intravesical instillation therapy. For patients with high-risk NMIBC after failure of bacillus Calmette\u2013Gu\u00e9rin (BCG) therapy, radical cystectomy and urinary diversion are the standard of care, which can be associated with a high morbidity and impaired quality of life. Developing efficacious bladder-sparing strategies is an unmet need for such patients. We conducted a systematic review of prospective interventional studies on NMIBC after BCG failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We comprehensively searched the Cochrane Database, PubMed and ClinicalTrials.gov to identify prospective studies on NMIBC after BCG failure from their inception up to June 2025. Search results were summarised according to types of agents by focusing on efficacy. To assess the risk of bias, the Methodological Index for Non-Randomized Studies was used for single-arm studies, while the Risk of Bias 2.0 tool was applied to randomised controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2493 studies screened, 114 studies met the eligibility criteria, of which most were early-phase or single-arm trials. Types of agents or modalities used included immunotherapy and biological response modifiers, cytotoxic anticancer drugs, immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors, antibody\u2013drug conjugates, radiotherapy and photodynamic therapy; of these, the former three accounted for more than 80% of the eligible trials. Among 37 published studies, complete response (CR) rates in patients with carcinoma in situ with or without papillary NMIBC ranged from 8% to 84%,\u2009and 12-month recurrence-free survival rates ranged from 20% to 86%. Interim reports of several ongoing trials using a novel intravesical drug delivery system of gemcitabine, gene therapy-based biological response modifiers with or without ICI, and a combination of ICI with anticancer agents demonstrated CR rates of 70% or higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review demonstrated the promising efficacy of novel bladder-sparing strategies for NMIBC after BCG failure. This review is limited by the predominance of early-phase trials and a limited number of comparative studies, offering only limited guidance for clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjonc-2025-000753","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:55:26Z","timestamp":1770015326000},"page":"e000753","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette\u2013Gu\u00e9rin failure: a systematic review"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct04640623","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04452591","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04752722","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03317158","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03892642","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04172675","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04172675","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02449239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06388720","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01259063","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04640623","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06211764","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07000084","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05024773","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06663137","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02982395","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06732531","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04498702","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04490993","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02773849","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06545955","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06929286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04452591","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04387461","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06567743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04752722","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06255964","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04799847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01200992","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05232136","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06971614","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02625961","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03711032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02808143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06972615","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03317158","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04149574","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06919965","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05014139","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06551233","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05996952","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05943379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05957757","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02449239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00981656","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03950362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06770582","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03945162","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01259063","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7086-8214","authenticated-orcid":false,"given":"Takahiko","family":"Soma","sequence":"first","affiliation":[{"name":"Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-6074","authenticated-orcid":false,"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, The Cancer Institute Hospital Of JFCR, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0623-3695","authenticated-orcid":false,"given":"Masahiro","family":"Toide","sequence":"additional","affiliation":[{"name":"Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0230-6367","authenticated-orcid":false,"given":"Masaya","family":"Ito","sequence":"additional","affiliation":[{"name":"Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-0085","authenticated-orcid":false,"given":"Fumitaka","family":"Koga","sequence":"additional","affiliation":[{"name":"Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"2026020122551936000_5.1.e000753.1","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.35278"},{"key":"2026020122551936000_5.1.e000753.2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"2026020122551936000_5.1.e000753.3","unstructured":"European Association of Urology . EAU guidelines on non-muscle-invasive bladder cancer. EAU Guidelines Office; 2025. Available: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer"},{"key":"2026020122551936000_5.1.e000753.4","unstructured":"National Comprehensive Cancer Network . NCCN guidelines: bladder cancer. version 1.2025. Plymouth Meeting, PA; 2025 Available: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417"},{"key":"2026020122551936000_5.1.e000753.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.16"},{"key":"2026020122551936000_5.1.e000753.6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","article-title":"Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort","volume":"81","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"key":"2026020122551936000_5.1.e000753.7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/2090598X.2019.1600279","article-title":"Trends in quality of life reporting for radical cystectomy and urinary diversion over the last four decades: A systematic review of the literature","volume":"17","author":"Rangarajan","year":"2019","journal-title":"Arab J Urol"},{"key":"2026020122551936000_5.1.e000753.8","unstructured":"Endo pharmaceuticals inc. valstar (valrubicin) intravesical solution: US prescribing information. Malvern, PA: Endo Pharmaceuticals; 2009. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020892s013lbl.pdf"},{"key":"2026020122551936000_5.1.e000753.9","unstructured":"US Food and Drug Administration . Bacillus calmette-guerin-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment \u2013 guidance for industry. Silver Spring, MD: FDA; 2018. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and"},{"key":"2026020122551936000_5.1.e000753.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"2026020122551936000_5.1.e000753.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2026020122551936000_5.1.e000753.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"2026020122551936000_5.1.e000753.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026020122551936000_5.1.e000753.14","unstructured":"Oncology insights: first-in-class bladder cancer therapy and the bacillus Calmette-Gu\u00e9rin shortage. Oncology Insights; 2025. Available: https:\/\/www.primetherapeutics.com\/oncology-insights-first-in-class-bladder-cancer-therapy-and-the-bacillus-calmette-gu%C3%A9rin-bcg-shortage"},{"key":"2026020122551936000_5.1.e000753.15","unstructured":"US Food and Drug Administration . FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer. 2025. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer"},{"key":"2026020122551936000_5.1.e000753.16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.urolonc.2024.12.264","article-title":"Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer","volume":"43","author":"Daneshmand","year":"2025","journal-title":"Urol Oncol"},{"key":"2026020122551936000_5.1.e000753.17","unstructured":"US Food and Drug Administration . NDA 20\u2013892: valstar (valrubicin) approval documents. Silver Spring, MD: FDA; 2001. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20892.cfm"},{"key":"2026020122551936000_5.1.e000753.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67799-3"},{"key":"2026020122551936000_5.1.e000753.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.05.004"},{"key":"2026020122551936000_5.1.e000753.20","doi-asserted-by":"publisher","DOI":"10.1177\/1756287214541798"},{"key":"2026020122551936000_5.1.e000753.21","doi-asserted-by":"crossref","first-page":"102313","DOI":"10.1016\/j.clgc.2025.102313","article-title":"Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Gu\u00e9rin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review","volume":"23","author":"Kulkarni","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"2026020122551936000_5.1.e000753.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2720"},{"key":"2026020122551936000_5.1.e000753.23","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"2026020122551936000_5.1.e000753.24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0b013e3283324d83","article-title":"Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial","volume":"21","author":"Perdon\u00e0","year":"2010","journal-title":"Anticancer Drugs"},{"key":"2026020122551936000_5.1.e000753.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.031"},{"key":"2026020122551936000_5.1.e000753.26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24914"},{"key":"2026020122551936000_5.1.e000753.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8199"},{"key":"2026020122551936000_5.1.e000753.28","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.jamcollsurg.2016.06.293","article-title":"Chemotherapeutic Role of Intravesical Gemcitabine and Mitomycin C for High-Risk Nonmuscle Invasive Bladder Carcinoma: A Randomized Trial","volume":"223","author":"Jayant","year":"2016","journal-title":"J Am Coll Surg"},{"key":"2026020122551936000_5.1.e000753.29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BLC-170095","article-title":"Single Arm Phase I\/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)","volume":"3","author":"Dalbagni","year":"2017","journal-title":"Bladder Cancer"},{"key":"2026020122551936000_5.1.e000753.30","unstructured":"ESMO . TAR-200 + cetrelimab and cetrelimab alone in patients with bcg-unresponsive high-risk nmibc \u2013 updated results from sunrise-1. UroToday; 2024. Available: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2024\/esmo-2024-bladder-cancer\/154852-esmo-2024-tar-200-cetrelimab-and-cetrelimab-alone-in-patients-with-bcg-unresponsive-high-risk-nmibc-updated-results-from-sunrise-1.html"},{"key":"2026020122551936000_5.1.e000753.31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","article-title":"Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non\u2013muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Gu\u00e9rin Therapy","volume":"103","author":"Robins","year":"2017","journal-title":"Urology"},{"key":"2026020122551936000_5.1.e000753.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.112"},{"key":"2026020122551936000_5.1.e000753.33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu\u00e9rin in Patients with Bacillus Calmette-Gu\u00e9rin-Unresponsive Non-Muscle Invasive Bladder Cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2026020122551936000_5.1.e000753.34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"key":"2026020122551936000_5.1.e000753.35","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0707-z"},{"key":"2026020122551936000_5.1.e000753.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.005"},{"key":"2026020122551936000_5.1.e000753.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3\u2009years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"2026020122551936000_5.1.e000753.38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2017.35.6_suppl.303","article-title":"An oral methionine aminopeptidase II inhibitor for high-risk non-muscle invasive bladder cancer relapsed after intravesical therapies: Update of a phase II trial","volume":"35","author":"Ye","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026020122551936000_5.1.e000753.39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026020122551936000_5.1.e000753.40","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004020"},{"key":"2026020122551936000_5.1.e000753.41","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"2026020122551936000_5.1.e000753.42","unstructured":"Tyson M . Groundbreaking cretostimogene grenadenorepvec monotherapy data demonstrates sustained, durable complete responses in high-risk bcg-unresponsive nonmuscle-invasive bladder cancer. UroToday; 2024. Available: https:\/\/www.urotoday.com\/conference-highlights\/suo-2024\/suo-2024-press-releases\/156695-groundbreaking-cretostimogene-grenadenorepvec-monotherapy-data-demonstrates-sustained-durable-complete-responses-in-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html"},{"key":"2026020122551936000_5.1.e000753.43","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2024.42.16_suppl.4601","article-title":"Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026020122551936000_5.1.e000753.44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.2025.43.5_suppl.802","article-title":"Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","volume":"43","author":"Taylor","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026020122551936000_5.1.e000753.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.073"},{"key":"2026020122551936000_5.1.e000753.46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/BLC-190211","article-title":"A Clinical Trial of the Intradermal TLR2 Agonist CADI-05 for BCG Recurrent and Unresponsive Non-Muscle Invasive Bladder Cancer","volume":"5","author":"O\u2019Donnell","year":"2019","journal-title":"Bladder Cancer"},{"key":"2026020122551936000_5.1.e000753.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.109"},{"key":"2026020122551936000_5.1.e000753.48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"key":"2026020122551936000_5.1.e000753.49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24617"},{"key":"2026020122551936000_5.1.e000753.50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euo.2021.12.006","article-title":"A Phase 1\/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Gu\u00e9rin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06\/14","volume":"5","author":"Rentsch","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026020122551936000_5.1.e000753.51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417535","article-title":"OncoTherad\u00ae (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Gu\u00e9rin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway","volume":"24","author":"Alonso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026020122551936000_5.1.e000753.52","first-page":"4192","article-title":"Advances in the clinical development of oncolytic viruses","volume":"14","author":"Li","year":"2022","journal-title":"Am J Transl Res"},{"key":"2026020122551936000_5.1.e000753.53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"2026020122551936000_5.1.e000753.54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Gu\u00e9rin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"key":"2026020122551936000_5.1.e000753.55","unstructured":"A phase 1\/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in bcg-unresponsive non-muscle-invasive bladder cancer patients (hcrn gu16-243 adapt-bladder cohort 4). UroToday; 2025. Available: https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2025\/asco-gu-2025-bladder-cancer\/158301-asco-gu-2025-a-phase-1-2-trial-of-durvalumab-plus-intravesical-gemcitabine-and-docetaxel-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-patients-hcrn-gu16-243-adapt-bladder-cohort-4.html"},{"key":"2026020122551936000_5.1.e000753.56","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2023.41.6_suppl.504","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non\u2013muscle-invasive bladder cancer (IR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: Cohort 3 interim analysis","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026020122551936000_5.1.e000753.57","unstructured":"First safety and efficacy results of the tar210 erdafitinib intravesical delivery system in patients with nonmuscle-invasive bladder cancer with select fgfr alterations. UroToday; 2024. Available: https:\/\/www.urotoday.com\/conference-highlights\/aua-2024\/aua-2024-bladder-cancer\/151853-aua-2024-first-safety-and-efficacy-results-of-the-tar-210-erdafitinib-intravesical-delivery-system-in-patients-with-non-muscle-invasive-bladder-cancer-with-select-fgfr-alterations.html"},{"key":"2026020122551936000_5.1.e000753.58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2267"},{"key":"2026020122551936000_5.1.e000753.59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"2026020122551936000_5.1.e000753.60","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10637-018-00716-w","article-title":"Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer","volume":"37","author":"Zahoor","year":"2019","journal-title":"Invest New Drugs"},{"key":"2026020122551936000_5.1.e000753.61","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1200\/JCO.2023.41.16_suppl.4596","article-title":"A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104)","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026020122551936000_5.1.e000753.62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","article-title":"Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026020122551936000_5.1.e000753.63","article-title":"PD03-02\u2003PHASE 3 RESULTS OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"},{"key":"2026020122551936000_5.1.e000753.64","unstructured":"Bio S . Sesen bio receives complete response letter from FDA for vicineum (oportuzumab monatox-qqrs) for BCG-unresponsive NMIBC. Cambridge, MA: Sesen Bio via Business Wire; 2021. Available: https:\/\/www.businesswire.com\/news\/home\/20210813005377\/en\/Sesen-Bio-Receives-Complete-Response-Letter-from-FDA-for-Vicineum-oportuzumab-monatox-qqrs"},{"key":"2026020122551936000_5.1.e000753.65","unstructured":"Bio S . Sesen Bio announces strategic decision to pause clinical development of Vicineum in the US. Business Wire; 2022. Available: https:\/\/www.businesswire.com\/news\/home\/20220718005213\/en\/Sesen-Bio-Announces-Strategic-Decision-to-Pause-Clinical-Development-of-Vicineum%E2%84%A2-in-the-US"},{"key":"2026020122551936000_5.1.e000753.66","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026020122551936000_5.1.e000753.67","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.2023.41.6_suppl.528","article-title":"A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis)","volume":"41","author":"Kulkarni","year":"2023","journal-title":"JCO"},{"key":"2026020122551936000_5.1.e000753.68","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1245\/s10434-022-12692-w","article-title":"Robotic Versus Open Cystectomy for Bladder Cancer: Synthesizing the Data from Current Systematic Reviews and Meta-Analyses","volume":"30","author":"Aminoltejari","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026020122551936000_5.1.e000753.69","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00345-020-03385-8","article-title":"Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases","volume":"39","author":"Clement","year":"2021","journal-title":"World J Urol"},{"key":"2026020122551936000_5.1.e000753.70","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22556"},{"key":"2026020122551936000_5.1.e000753.71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09537.x"},{"key":"2026020122551936000_5.1.e000753.72","unstructured":"US Food and Drug Administration . Understanding unapproved use of approved drugs & their risks. Silver Spring, MD: FDA. 2024 Available: https:\/\/www.fda.gov\/patients\/learn-about-expanded-access-and-other-treatment-options\/understanding-unapproved-use-approved-drugs-label"},{"key":"2026020122551936000_5.1.e000753.73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.36469\/jheor.2024.124208","article-title":"Adherence to First-Line Intravesical Bacillus Calmette-Gu\u00e9rin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer","volume":"11","author":"Gaylis","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"key":"2026020122551936000_5.1.e000753.74","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/iju.14933","article-title":"Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Gu\u00e9rin treatment","volume":"29","author":"Miyake","year":"2022","journal-title":"Int J Urol"},{"key":"2026020122551936000_5.1.e000753.75","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"2026020122551936000_5.1.e000753.76","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6230409","article-title":"Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Gu\u00e9rin for Bladder Cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J Oncol"},{"key":"2026020122551936000_5.1.e000753.77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu\u00e9rin-exposed High-risk Non-muscle-invasive Bladder Cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"2026020122551936000_5.1.e000753.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.073"},{"key":"2026020122551936000_5.1.e000753.79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urolonc.2021.07.007","article-title":"Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start","volume":"40","author":"Hurle","year":"2022","journal-title":"Urol Oncol"},{"key":"2026020122551936000_5.1.e000753.80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"2026020122551936000_5.1.e000753.81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J Urol"},{"key":"2026020122551936000_5.1.e000753.82","first-page":"317","article-title":"Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder","volume":"101","author":"Cervenakov","year":"2000","journal-title":"Bratisl Lek Listy"},{"key":"2026020122551936000_5.1.e000753.83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0090-4295(96)90059-X","article-title":"Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial","volume":"48","author":"Sarosdy","year":"1996","journal-title":"Urology"},{"key":"2026020122551936000_5.1.e000753.84","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.eururo.2024.12.018","article-title":"Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group","volume":"87","author":"Fragkoulis","year":"2025","journal-title":"Eur Urol"},{"key":"2026020122551936000_5.1.e000753.85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A Phase 1b\/2 Study of Atezolizumab with or Without Bacille Calmette-Gu\u00e9rin in Patients with High-risk Non-muscle-invasive Bladder Cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2026020122551936000_5.1.e000753.86","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2025-000753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:55:35Z","timestamp":1770015335000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2025-000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjonc-2025-000753"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2025-000753","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}